1. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
- Author
-
Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, and Daniel-Ribeiro CT
- Subjects
- Animals, Antibodies immunology, Antigens, Protozoan administration & dosage, Antigens, Protozoan immunology, Fluorescent Antibody Technique, Immunologic Memory drug effects, Immunologic Memory immunology, Malaria Vaccines administration & dosage, Malaria Vaccines immunology, Peptides administration & dosage, Peptides immunology, Peptides pharmacology, Protozoan Proteins administration & dosage, Protozoan Proteins immunology, Saimiri, Antibodies blood, Antigens, Protozoan pharmacology, Malaria Vaccines pharmacology, Malaria, Falciparum prevention & control, Plasmodium falciparum immunology, Protozoan Proteins pharmacology
- Abstract
The immunogenicity and protective efficacy of various antigen-adjuvant formulations derived either from the merozoite-surface protein-3 (MSP-3) or the glutamate-rich protein (GLURP) of Plasmodium falciparum were evaluated in Saimiri sciureus monkeys. These proteins were selected for immunogenicity studies based primarily on their capacity of inducing an antibody-dependent cellular inhibition effect on parasite growth. Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens.
- Published
- 2004
- Full Text
- View/download PDF